The "Friends of the German Cancer Research Center" association supports the DKFZ and aims to help strengthen its position in international competition. With the DKFZ Innovation Award presented at this year's DKFZ annual reception, the association honored Titus Brinker as a researcher whose highly innovative work builds a bridge from research to practical application with commercialization potential.

Stem cell research - 14/03/2024

Using organoids to gain a better clinical understanding of pancreatic cancer

Prof. Dr. Alexander Kleger carries out translational research at Ulm University Hospital to gain a better understanding of pancreatic ductal adenocarcinoma (PDAC) and develop individualised treatments. He and his team are using organoid models and stem cell-based systems and have succeeded in simultaneously cultivating all three main cell types of the pancreas from pluripotent stem cells.

Expert interview - 08/03/2023

How do new active substances from university research reach patients?

Access to capital remains one of the biggest challenges in the life sciences sector. Over the last two years, the Baden-Württemberg Center for Academic Drug Discovery (BWCAD2) has successfully implemented a model of cooperation between academic drug research and industry for the development and validation of therapeutic concepts. Dr. Barbara Jonischkeit spoke with the initiator and leading figure behind the BWCAD2 project, Prof. Dr. Stefan Laufer

On March 23, 2022, the U.S. Food and Drug Administration (FDA) granted approval to the first targeted radioligand therapy against metastatic prostate cancer based on a joint patent of the German Cancer Research Center (DKFZ) and the University of Heidelberg. The agent significantly improves the chances of survival for those affected.

A new interdisciplinary research project aims to uncover information that can help decode hereditary colon cancer with the aid of mathematical models. Mathematicians and tumour biologists of Heidelberg University, the Heidelberg Institute for Theoretical Studies, Heidelberg University Hospital, and the German Cancer Research Center are collaborating on the project.

Stem cell therapy for regenerating intervertebral discs - 16/07/2020

Ulm’s simulator has Europe’s back

Back pain is often caused by intervertebral disc disorders. Much has already been tried and is available to help patients. Despite extensive progress, there is still no surefire recipe for success. iPSpine, an EU-funded project to which researchers from Ulm are contributing interdisciplinary engineering and biomedical expertise, aims to design a novel therapy for back pain based on intervertebral disc regeneration.

Translational oncology - 26/05/2020

Translation: driver of cancer medicine

The fight against cancer is a pressing issue. Although technological advances in the treatment, prevention and early detection of cancer have improved over the past few decades, the number of people affected is increasing. Cancer medicine now wants to counteract this by joining forces with other players involved in the field.

Company profile - 16/12/2019

Velabs Therapeutics GmbH: each droplet is a test system

Using microfluidics to detect new therapeutic antibodies is, in simple terms, the concept developed by Velabs Therapeutics GmbH. The Heidelberg-based start-up was spun out from the European Molecular Biology Laboratory (EMBL) in 2017 with the support of EMBLEM Technology Transfer GmbH. More recently, investors have provided the young company with additional funding to expand its technologies and applications.

Article - 08/11/2019

Nanorobots as future minimally invasive tools for the eye

It is difficult to place drugs in the right place in the eye. When using droplets, only a small fraction of the drug reaches its target. Injecting drugs into the eye is also more a matter of luck than judgement. Basic researchers at the Max Planck Institute for Intelligent Systems Stuttgart have developed a nanorobot that can be loaded with active ingredients for treating eye diseases and directed through the solid tissue of the vitreous body.

Vision Zero in oncology - 02/09/2019

Call for a comprehensive master plan for preventing and treating cancer

While a cancer-free world may seem unrealistic given the increasing numbers of cancer cases, we need to reach a social consensus that cancer deaths are unacceptable and that everything possible must be done to prevent them. Leading cancer researchers around the world are calling for more investment in prevention research and cancer screening to move towards the vision of a near cancer-free world.

Article - 05/03/2019

Vaccination against oncogenic Epstein-Barr viruses

Almost all humans are infected with Epstein-Barr viruses (EBV), which are linked to the development of benign diseases such as infectious mononucleosis as well as several cancers. Scientists from the German Cancer Research Center have developed a new strategy for creating a vaccine that targets different EBV virus life phases and has the potential to provide effective protection against EBV infection.